Elusys Therapeutics Finalizes HHS Contract to Deliver Anthim®, its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services January 31, 2022
Obiltoxaximab receives marketing authorization from European Commission for the treatment of Inhalation Anthrax December 2, 2020
Elusys Therapeutics receives Health Canada approval for Anthim® for the treatment for Inhalation Anthrax August 12, 2020
Elusys receives second delivery order from U.S. government for Anthim®, its treatment for Inhalation Anthrax April 23, 2018
Elusys delivers first shipment of ANTHIM®, its treatment for Inhalational Anthrax, to U.S. Government Strategic National Stockpile October 10, 2017
Elusys Therapeutics Announces Publication of Data Establishing the Adult Human Dose for its Inhalational Anthrax Antitoxin ANTHIM® (Obiltoxaximab) Injection December 20, 2016
Elusys Therapeutics Announces Publication of Results from Five Clinical Trials with its Inhalational Anthrax Antitoxin ANTHIM® (Obiltoxaximab) Injection September 14, 2016
Elusys Therapeutics Announces that Manuscripts for its Anthrax Antitoxin, ANTHIM® (Obiltoxaximab) Injection, have been Accepted for Publication July 20, 2016
Elusys Therapeutics Receives FDA Approval for ANTHIM® (Obiltoxaximab) Injection for the Treatment and Prophylaxis of Inhalational Anthrax March 21, 2016
Elusys Therapeutics Receives First Delivery Order from U.S. Government for ANTHIM® (Obiltoxaximab) for Treatment of Inhalational Anthrax November 12, 2015
Elusys Awarded Additional $16 Million Under Existing U.S. Government Contract to Complete Development of Lyophilized Form of ANTHIM® (Obiltoxaximab) for Treatment of Inhalational Anthrax October 6, 2015
U.S. Food and Drug Administration Accepts Biologics License Application for ANTHIM (Obiltoxaximab) June 1, 2015
Elusys Reports Efficacy of its Anthrax Anti-Toxin In Post-Exposure Prophylaxis In Animal Studies February 12, 2015
Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program September 22, 2014
Elusys Completes Commercial Manufacturing Process Validation for Anthrax Antitoxin ETI-204 April 8, 2014
Elusys Receives Notice of Allowance from U.S. Patent Office for Methods of Preventing or Treating Anthrax with ETI-204, an Anti-Anthrax Antibody, via Intramuscular Injection March 10, 2014
Elusys Completes Enrollment In Three Phase 3 Safety Studies Of Its Anthrax Anti-toxin, ETI-204, In Adult Volunteers February 5, 2014
Elusys Reports Its Anti-toxin Achieved 100% Survival Rate Following Anthrax Challenge In Pre-treatment Animal Study January 30, 2014
Elusys Therapeutics presents efficacy results and other key findings on ETI-204 Anthrax anti-toxin September 5, 2013
Elusys releases new data on Anthrax anti-toxin administered via intramuscular injection from three recent animal studies July 31, 2013
Alliance for biosecurity elects Chief Executive Officers of Bavarian Nordic and Elusys Therapeutics as new co-chairs July 1, 2013
Elusys awarded additional $14.5 million under existing U.S. government contracts supporting expanded human safety studies of ETI-204 for treatment of inhalational anthrax September 13, 2012
Elusys awarded additional $50.2 million under an existing U.S. government contract to support final stages of development of ETI-204, for treatment of inhalational Anthrax August 1, 2012
Elusys initiates third clinical safety study of Anthim, a new anthrax treatment; company successfully completes manufacturing at commercial scale October 24, 2011
Elusys awarded $68 million contract to develop Anthim for intramuscular pre- and post-exposure prophylaxis of anthrax infection September 8, 2011
Regulatory Affairs Executive, Greg Torre, PhD, Esq, Joins Elusys Therapeutics Management Team January 11, 2011
Elusys Awarded Additional $40.6 Million Under Exisiting US Government Contract To Fund Advanced Development Of Anthim, A New Treatment For Anthrax August 4, 2010
Elusys Therapeutics and Lonza Extend Manufacturing Agreement For Anthim, a New Anthrax Treatment In Late-Stage Development July 15, 2010
Elusys Receives Contract for up to $143 Million from the US Federal Government to Fund Advanced Development of Anthim®, a New Treatment for Anthrax January 4, 2010
Elusys Presents Data from Anthim® Anthrax Anti-toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day December 7, 2009
Elusys’ Anthim™ Dramatically Improves Survival of Animals Treated After Active Anthrax Infection April 22, 2008
